Published July 13, 2026
Two Price Tags, One Product
Twenty-four dollars. That’s what a one-gram THC vape cartridge costs on sale in Metropolis, Illinois.
One hundred thirty dollars. That’s what Ricky Hunt paid for the equivalent product at his licensed dispensary in Kentucky.
Hunt, 60, of Hopkinsville, was diagnosed with spinal cord cancer at age ten. “They stopped it from killing me, but I have all the pain of an end-of-life patient,” he told Kentucky lawmakers this month, testifying by video because he’s bedridden. Until July 1, he managed his costs the way thousands of Kentucky patients did — driving across the border, protected by an executive order from Gov. Andy Beshear that pardoned out-of-state purchases. That order expired June 15, with the in-state-only rule taking hold July 1. Now Hunt’s medicine costs five times more, insurance covers none of it, and the state’s own dispensaries have intermittently closed for lack of supply.
Every outlet covering this has framed it as a Kentucky story. It’s not. It’s a market design story — and for the operators, investors, and policymakers watching the next wave of state launches, it’s the clearest case study yet in how a legal cannabis market’s rules determine its prices before a single seed goes in the ground.
The Math Was Never Going to Work
Start with the supply architecture Kentucky wrote into law. The state licenses exactly 16 cultivators. Only two of them may grow up to 25,000 square feet; the statewide total is capped at 115,000 square feet of canopy.
For scale: that’s about 2.6 acres — for a state of 4.5 million people with an estimated 400,000 residents eligible for the program. Single commercial greenhouses in Michigan or Illinois exceed Kentucky’s entire statewide allowance. Add the requirement that all cultivation happen indoors — the most expensive way to grow cannabis, in a state with abundant farmland and a legendary growing heritage — and Kentucky guaranteed both scarce supply and high production costs in the same statute.
Then, on July 1, the state removed the only competition its growers had. While the Beshear pardon order stood, Illinois and Michigan effectively were Kentucky’s supply — mature, high-volume markets where, as the state’s own industry association director put it, gummies sell for two and three dollars a bag. Sealing the border didn’t create Kentucky’s price problem. It revealed it. In-state prices now average about $40 per unit for edibles and north of $100 for vapes, and there’s nothing forcing them down.
Sixteen licenses. A lottery, not a merit process — 584 applicants competed for those 16 cultivation slots. No home cultivation as a pressure valve. Indoor-only mandates. Closed borders. Each rule has a defensible rationale in isolation. Stacked together, they’re a machine for exactly the outcome playing out in that committee room.
The Feedback Loop That Keeps It Broken
Here’s the part that should worry Kentucky’s licensees, not just its patients. As of the end of June, the state had about 26,000 registered cardholders — roughly 6.5% of the eligible population, and barely up from 24,000 at the start of the year.
Why would enrollment stall in a state with 400,000 eligible patients? Because the value proposition is broken. Pay for a doctor’s certification and a card, so you can buy $130 cartridges that cost $24 across the river — or, more realistically, that cost less than that from the unregulated market that never left. Rachel Roberts, who runs the Kentucky Cannabis Industry Alliance, said it plainly to lawmakers: “Without expanding access, the high price floor will continue.”
That’s the loop: constrained supply keeps prices high, high prices keep enrollment low, low enrollment keeps the market too small to justify capacity expansion, and small capacity keeps supply constrained. Meanwhile Rep. Myron Dossett — the Republican committee co-chair, not a legalization activist — warned that the state is steering patients “toward the streets.” He’s describing the loop’s exit ramp: the illicit market, which charges no card fee and honors no border.
Who Actually Wins This Design
Follow the incentives and Kentucky’s structure has one clear winner: the sixteen cultivation license holders. They operate in the highest-margin medical market in the region, with statutory protection from both in-state competition (the cap) and out-of-state competition (the border rule). That 5x price premium is their revenue. The 584-to-16 application ratio tells you the market understood exactly what those golden tickets were worth.
This is the political economy every limited-license state creates: scarcity rents for winners, paid for by patients. And it’s why these regimes are simultaneously lucrative and fragile. Rep. Ryan Bivens told the same hearing the quiet part out loud: “Maybe we just need to can this and open it back up so they can go to other states… I think we’re wasting a whole lot of money.” When Republican legislators in a young medical program start musing about scrapping it, license holders should hear a clock ticking.
The Fair Counterarguments — and Why They Don’t Save the Design
Two rebuttals from the hearing deserve honest weight. Sam Flynn of the state’s Office of Medical Cannabis noted that five of Kentucky’s seven neighbors launched programs earlier, and young markets are always pricier than mature ones. True — but design determines how fast that gap closes. Ohio launched adult-use sales in 2024 and grew regulated revenue 61.6% in its first full year precisely by licensing enough supply to pull its residents back from Michigan; New York halved its price problem by nearly doubling its store count in a year. Youth explains some premium. A 115,000-square-foot statewide ceiling explains five-x.
Roberts’s safety argument — Kentucky product is tested to Kentucky standards, Michigan’s cheap volume isn’t — is also legitimate. But testing regimes don’t require a 16-grower cap. Every mature market manages to test product at a fraction of Kentucky’s prices.
The Lesson for Everyone Else
More states will launch programs in the next three years, and each will face the same fork Kentucky faced: protect a small set of licensees, or provision supply for the actual patient population. The Kentucky case now provides the cleanest natural experiment yet on what the first path costs — a 5x patient premium, single-digit enrollment, supply outages, bipartisan buyer’s remorse, and a thriving illicit competitor — all within seven months of launch.
For operators and investors, the playbook implication cuts both ways. Limited-license states offer the best unit economics in cannabis while they last — Kentucky’s licensees are proof. But the same design that creates those margins generates the political pressure that eventually dismantles them. Underwrite accordingly.
Regulators like to say prices will come down as capacity comes online. In Kentucky, capacity is capped by statute. The prices aren’t a growing pain. They’re the design, working as written.
For the market data behind the Ohio and New York comparisons, see our breakdown of the industry’s first-ever sales decline — and follow the rest at our Cannabis Business hub.
Sources:
WKU Public Radio / WKMS (the original reporting — Hunt testimony, price figures, enrollment data, official quotes): https://www.wkyufm.org/news/2026-07-08/no-longer-able-to-purchase-out-of-state-ky-medical-cannabis-patients-suffer-sticker-shock
MJBizDaily (supply structure — 16 cultivators, 115,000 sq ft cap, 584 applications): https://mjbizdaily.com/news/why-kentucky-medical-marijuana-is-so-expensive/616848/
Kentucky New Era (committee hearing detail, Flynn and Roberts testimony, lottery process): https://www.kentuckynewera.com/cadiz_record/news/article_18dd2a9a-1c92-514b-8a5e-9da0c950e7cf.html
Marijuana Policy Project — Kentucky program summary (SB 47 details, executive order timeline, program stats): https://www.mpp.org/states/kentucky/